Medicare's $274 Semaglutide Price in 2027: What You'll Actually Pay
Price verification — October 26, 2026
This article includes an older pricing snapshot. Older amounts, coupons and annual totals below are historical illustrations, not current checkout quotes.
- Wegovy (semaglutide): Wegovy tablet: $149/30 tablets at 1.5 mg, $199 at 4 mg (a temporary $149 4 mg offer may apply), and $299 at 9 mg or 25 mg. Wegovy injection: eligible new patients may pay $199 per 28-day fill for the first two fills at 0.25 or 0.5 mg through Dec. 31, 2026, then generally $349 for standard pen doses. Eligibility and dosage restrictions apply. Official source
- Clinical program fees: Ivím lists a $74.99/month membership with medication billed separately. Sesame lists care from $59/month on a 12-month commitment; month-to-month costs more, and medication is separate. These are care fees, not all-inclusive drug prices. Official source
- Sesame annual-commitment terms: Official source.
These are manufacturer self-pay or listed care-fee examples, not one all-inclusive price or guaranteed prescription. Insurers, clinical visits, pharmacy choice, dosage, supplies, refill conditions and geography can change the amount due.
Starting January 1, 2027, Medicare's negotiated price for semaglutide (Ozempic, Rybelsus and Wegovy) is $274 for a 30-day supply, but that is the price Medicare uses for the drug, not your copay. If your Part D plan charges a percentage of the drug's price, or you are still in your deductible, your cost should fall. If you pay a flat copay, already hit the yearly cap, or get Wegovy for weight loss through the $50 Bridge, the $274 price changes little or nothing for you.
Key takeaways
- CMS set semaglutide's negotiated price at $274 for a 30-day supply, against a 2024 list price of $959, effective January 1, 2027.
- Package prices differ: $276.78 for an Ozempic 4 mg pen or 30 Rybelsus 7 mg tablets, and $385.63 for a four-pen box of Wegovy 2.4 mg.
- It applies only to Medicare Part D, not to employer plans or cash purchases.
- Coinsurance and deductible-phase costs fall the most. Flat copays may not change.
- Wegovy for weight loss alone stays outside Part D; Medicare covers it through the $50 GLP-1 Bridge through December 31, 2027.
Figures checked October 19, 2026 against CMS, Medicare.gov and the sources linked below. Your plan's 2027 documents control what you pay, so confirm in writing with the plan.
What CMS actually announced
In November 2025, CMS published negotiated prices for 15 Part D drugs that take effect January 1, 2027. Semaglutide, sold as Ozempic, Rybelsus and Wegovy, is listed at $274 for a 30-day supply versus a 2024 list price of $959, a 71% discount (CMS fact sheet). CMS reports that Part D gross spending on semaglutide was about $15.2 billion in 2024, across 2,282,000 enrollees who used it.
The $274 figure is a summary. The same fact sheet lists prices by package:
| Product and package | Negotiated price (2027) |
|---|---|
| Semaglutide, 30-day supply (summary figure) | $274 |
| Ozempic 4 mg/3 mL pen (1 pen) | $276.78 |
| Rybelsus 7 mg (30 tablets) | $276.78 |
| Wegovy 2.4 mg/0.75 mL (4 pens) | $385.63 |
| 2024 list price, 30-day supply (for comparison) | $959 |
Source: CMS, Negotiated Prices for Initial Price Applicability Year 2027. Checked October 19, 2026.
Across all 15 drugs, CMS estimates $685 million in out-of-pocket savings in 2027 for people with Medicare drug plans, based on 2024 enrollment and use (CMS infographic). That is a program-wide estimate, not a per-person promise.
Why $274 is not your copay
The negotiated price, officially the "maximum fair price," is what the drug costs within Part D. Your plan then applies its own benefit design on top: a deductible, a tier, and either a flat copay or a percentage (coinsurance). KFF explains that enrollees who pay coinsurance "could see savings from a Medicare-negotiated price that is lower than their plan's negotiated price" (KFF negotiation FAQ).
The practical result: some enrollees will see a large drop in what they pay, and others will see little or none, depending on plan design.
Who is most likely to pay less
- Coinsurance plans. A percentage of a lower price is a lower dollar amount.
- Anyone in the deductible. In the deductible phase you pay the drug's full cost under your plan, so a lower price means a smaller January bill. No Part D plan can have a deductible above $700 in 2027 (Medicare.gov).
- People who would not have hit the cap. The 2027 out-of-pocket cap is $2,400 (Medicare.gov). If a lower price keeps your yearly total under the cap, you keep the difference.
Who may see little or no change
- Flat-copay plans. If your plan charges a fixed amount per fill after the deductible, a lower drug price does not automatically lower it.
- People who hit the $2,400 cap anyway because of other expensive drugs.
- Wegovy users covered through the Bridge, who pay $50 a month outside Part D.
A worked example (hypothetical)
The table below is illustrative only. It assumes one 30-day fill a month, no other drugs, the full 2027 maximum deductible of $700, and a hypothetical 25% coinsurance after the deductible. It compares the $959 list price with the $274 negotiated price. Plans' actual pre-2027 prices are not public and were likely below list, so real-world savings will usually be smaller than this table shows.
| Hypothetical scenario | Drug priced at $959 | Drug priced at $274 |
|---|---|---|
| Yearly drug cost (12 fills) | $11,508 | $3,288 |
| January fill (you pay) | $764.75 ($700 deductible + 25% of $259) | $274 (all toward deductible) |
| Typical fill after deductible | $239.75 | $68.50 |
| Your yearly total | $2,400 (reaches the cap in August) | $1,347 (never reaches the cap) |
Hypothetical math using the 2027 $700 maximum deductible and $2,400 cap from Medicare.gov, and prices from the CMS fact sheet. The 25% rate is an assumption, not your plan's rate.
At $274, it takes about two and a half fills to clear the $700 deductible, so January, February and part of March carry most of the cost. If those early bills are hard to absorb, see our guide to the Medicare Prescription Payment Plan, which spreads Part D costs across the year.
Not covered by Part D?
If your plan will not cover semaglutide for your diagnosis, you can see what self-pay programs currently charge; partner programs cannot bill Medicare.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
The price only applies inside Part D
CMS describes these as negotiated prices for Medicare Part D drugs, made available to people with Medicare and the pharmacies that dispense to them (CMS fact sheet). That means:
- Employer and marketplace plans set their own prices for Ozempic and Wegovy.
- Cash purchases use the manufacturer's self-pay prices, which are a separate channel. Novo lists most Ozempic pen doses at $349 a month for existing self-pay patients as of October 2026 (Ozempic savings page).
- Medicare enrollees cannot use Novo's copay savings card. Its terms exclude anyone "enrolled in any federal or state health care program with prescription drug coverage," naming Medicare (NovoCare terms).
Wegovy still needs a covered use
Part D is barred by law from covering drugs used specifically for weight loss. It can cover GLP-1s for other medically accepted uses, such as type 2 diabetes, cardiovascular risk reduction or sleep apnea (KFF). So the $385.63 Wegovy price matters only when your plan covers Wegovy for one of those uses.
For weight loss alone, Medicare covers Wegovy (injection or tablet) through the separate Medicare GLP-1 Bridge at a $50 monthly copay. That copay does not count toward your Part D deductible or out-of-pocket limit (Medicare.gov). CMS says the Bridge runs through December 31, 2027 (CMS). Medicare.gov also notes that people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge, but their Part D plan might cover a GLP-1.
The $245 price you may have heard about
Separately from negotiation, the administration reached pricing agreements with GLP-1 makers in late 2025. KFF reports that manufacturers agreed to a net price of $245 per 30-day supply for the drugs in the Medicare GLP-1 Bridge (KFF). The KFF and CMS materials cited here do not spell out how that $245 figure interacts with the $274 negotiated price for semaglutide claims under regular Part D in 2027, so treat any single headline number with caution.
For your wallet, the practical point is the same either way. What you pay in Part D is set by your plan's deductible, tier and copay or coinsurance applied to the price used for your claim. Ask your plan what it will charge per fill in 2027 rather than working backward from a headline number.
How pharmacies get paid, and why you might hear about it
Manufacturers must make the negotiated price available to pharmacies that dispense to Medicare patients (CMS fact sheet). CMS runs this through the Medicare Transaction Facilitator: pharmacies receive refunds in bank accounts they register there, manufacturers get up to 14 days to process claim data, and CMS reports that refunds have reached pharmacies within 21 days of the date of service on average (CMS MTF fact sheet, April 2026).
This is a pharmacy-side process. Your cost is still whatever your Part D plan's benefit says. If a pharmacy tells you it cannot fill a covered semaglutide prescription, call the number on your plan card for another in-network pharmacy.
What to do before January 1
- Find your plan's 2027 cost for your exact product and strength in Medicare Plan Finder or your Annual Notice of Change.
- Check whether it is a flat copay or coinsurance, and whether the deductible applies to that tier.
- If you use Wegovy, confirm whether your plan covers it for your diagnosis or whether you belong in the Bridge.
- Get the plan's answer in writing, or note the date and representative's name.
- Compare plans during Open Enrollment, which ends December 7, 2026. Our 2027 Part D plan guide for GLP-1 users walks through it.
Questions to ask your plan
- "What will I pay per fill for [Ozempic/Rybelsus/Wegovy, strength] in 2027, before and after the deductible?"
- "Is that a copay or coinsurance?"
- "Is the drug covered for my diagnosis, and does it need prior authorization?"
Compare care options before choosing a program
If Medicare will not cover your GLP-1 for your situation, compare current self-pay options and their published prices.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
Frequently asked questions
Will I pay $274 for Ozempic on Medicare in 2027?
Not necessarily. $274 for a 30-day supply is the negotiated price Medicare uses for semaglutide starting January 1, 2027. Your plan's deductible, tier and copay or coinsurance determine what you pay.
Who benefits most from the negotiated semaglutide price?
People whose plans charge coinsurance (a percentage of the price) and people still in their deductible, because both costs are tied to the drug's price. Flat-copay enrollees may see little change.
Does the $274 price apply to my employer plan or cash purchases?
No. The negotiated price applies to Medicare Part D. Employer plans and cash purchases use their own pricing, such as Novo Nordisk's separate self-pay prices.
Does the negotiated price cover Wegovy for weight loss?
Part D cannot cover drugs used only for weight loss. Medicare covers Wegovy for weight loss through the separate Medicare GLP-1 Bridge at a $50 monthly copay through December 31, 2027.
Is the Wegovy negotiated price also $274?
No. CMS lists a four-pen box of Wegovy 2.4 mg at $385.63. The $274 figure is a 30-day summary price, and an Ozempic 4 mg pen and 30 Rybelsus 7 mg tablets are each $276.78.
Sources
- Negotiated Prices for Initial Price Applicability Year 2027 fact sheet (CMS)
- Negotiated Prices IPAY 2027 infographic (CMS)
- FAQs About the Medicare Drug Price Negotiation Program (KFF)
- What to Know About the BALANCE Model and the Medicare GLP-1 Bridge (KFF)
- Save on Ozempic (Novo Nordisk)
- Ozempic Savings Offer terms (NovoCare)
- Weight loss drugs: Medicare GLP-1 Bridge (Medicare.gov)
- Medicare GLP-1 Bridge (CMS)
- Medicare Transaction Facilitator fact sheet for pharmacies (CMS, April 2026)
- Medicare.gov: Costs for Medicare drug coverage
Medical disclaimer: This article is general information, not medical advice, and does not replace a licensed clinician who knows your history. Approvals, labels, coverage and prices change; check the linked sources and talk with your prescriber or pharmacist before making decisions about any medication.